TY - JOUR T1 - Statin-induced lowering of LDL cholesterol associated with a reduced risk for cardiovascular events, not likely outweighed by the risk of diabetes, for people at low short-term risk of cardiovascular disease JF - Evidence Based Medicine JO - Evid Based Med SP - 142 LP - 143 DO - 10.1136/eb-2012-101028 VL - 18 IS - 4 AU - Robert Sidney Rosenson Y1 - 2013/08/01 UR - http://ebm.bmj.com/content/18/4/142.abstract N2 - Commentary on: Mihaylova B, Emberson J, Blackwell L, et al. Cholesterol TREATMENT Trialists’ (CTT) collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581–90.OpenUrlCrossRefPubMedWeb of Science Current guideline-based eligibility criteria for the statin therapy have incorporated estimates of risk reduction from randomised clinical trials of primary prevention in which individuals have been treated from an average 1.5–5 years, cost of treatment before the recent generic availability of potent statin agents, and potential harm associated with the use of treatment in a low-risk individual. Statins have been advocated for the primary prevention of cardiovascular disease (CVD) in patients with an estimated 5-year major CVD event risk ≥ 10%.1–3 The debate concerning the risks and benefits of the statin … ER -